Darrick Albert Carter
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$13.4MFederal grants as PI20 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
20 awards · $13.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 17, 2026 | NIH | SBIR Phase I LiT4Q TLR4 Agonist Formulation for Mucosal Melanoma | $391K | PAI LIFE SCIENCES INC |
| May 19, 2026 | NIH | SBIR Phase II A Vaccine for Lymphatic Filariasis, LFGuard™ | $714K | PAI LIFE SCIENCES INC |
| Mar 21, 2025 | NIH | SBIR Phase II A Vaccine for Lymphatic Filariasis, LFGuard™ | $453K | PAI LIFE SCIENCES INC |
| Dec 8, 2023 | NIH | SBIR Phase II A Vaccine for Lymphatic Filariasis, LFGuard™ | $995K | PAI LIFE SCIENCES INC |
| May 18, 2022 | NIH | SBIR Phase II A Vaccine for Lymphatic Filariasis, LFGuard™ | $1.0M | PAI LIFE SCIENCES INC |
| Feb 3, 2022 | NIH | SBIR Phase II A Vaccine for Schistosomiasis, "SchistoShield" | $506K | PAI LIFE SCIENCES INC |
| Sep 8, 2021 | NIH | SBIR Phase I Adjuvanted Recombinant Candidates to Prime / Boost COVID-19 RNA Vaccines | $243K | PAI LIFE SCIENCES INC |
| May 21, 2021 | NIH | SBIR Phase II A Vaccine for Lymphatic Filariasis, LFGuard™ | $1.0M | PAI LIFE SCIENCES INC |
| Feb 4, 2021 | NIH | SBIR Phase II A Vaccine for Schistosomiasis, "SchistoShield" | $506K | PAI LIFE SCIENCES INC |
| Aug 26, 2020 | NIH | SBIR Phase II JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer | $557K | PAI LIFE SCIENCES INC |
| Jun 23, 2020 | NIH | SBIR Phase II A Vaccine for Lymphatic Filariasis, LFGuard™ | $1.0M | PAI LIFE SCIENCES INC |
| Mar 12, 2020 | NIH | SBIR Phase II A Vaccine for Schistosomiasis, "SchistoShield" | $707K | PAI LIFE SCIENCES INC |
| Sep 19, 2019 | NIH | SBIR Phase II JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer | $721K | PAI LIFE SCIENCES INC |
| Feb 27, 2019 | NIH | SBIR Phase I Process Development for a Lymphatic Filariasis Vaccine, (LFGuard™) | $225K | PAI LIFE SCIENCES INC |
| Dec 29, 2017 | NIH | SBIR Phase II A Vaccine for Schistosomiasis, "SchistoShield" | $1.3M | PAI LIFE SCIENCES INC |
| Jul 26, 2017 | NIH | STTR Phase I CruziScreen, a recombinant antigen-based screening test for Chagas disease | $157K | PAI LIFE SCIENCES INC |
| Dec 30, 2016 | NIH | SBIR Phase II A Vaccine for Schistosomiasis, "SchistoShield" | $1.4M | PAI LIFE SCIENCES INC |
| Sep 20, 2016 | NIH | SBIR Phase I JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer | $200K | PAI LIFE SCIENCES INC |
| Feb 26, 2016 | NIH | SBIR Phase I A recombinant protein that increases engraftment of hematopoietic stem cells | $209K | PAI LIFE SCIENCES INC |
| Dec 29, 2015 | NIH | SBIR Phase II A Vaccine for Schistosomiasis, "SchistoShield" | $1.2M | PAI LIFE SCIENCES INC |
Peer ranks
Federal funding#31
Awards as PI#18
Patents#273
Companies
- PAI LIFE SCIENCES INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.